IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Clinitech Laboratory IPO is a book build IPO listing on BSE SME exchange. The company is based in Mumbai and caters to Healthcare sector. Inventure Merchant Banker Services Private is the merchant banker of Clinitech Laboratory IPO. It is a SME IPO which filed its Draft Red Herring Prospectus (DRHP) on 23rd January 2024.
Clinitech Laboratory IPO posted revenues of Rs 6.44 crores and PAT of Rs 0.37 crores in FY25 on annualised basis.Financial results of Clinitech Laboratory IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
Clinitech Laboratory IPO PAT Margin is 5.76%, ROCE (Return on Capital Employed) is 12.00% as per latest financial. The below table shows Clinitech Laboratory IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
The market Capitalisation of Clinitech Laboratory IPO is Rs 21.91 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Clinitech Laboratory IPO prospectus highlights an Return on Equity (ROE) of 15%, Return on Assets (ROA) of 12%, and an EBITDA Margin of 18%, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Clinitech Laboratory IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Clinitech Laboratory IPO is ₹21.91 Cr, based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Clinitech Laboratory IPO has a Price-to-Earnings (PE) ratio of 59.03 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Clinitech Laboratory IPO reported revenue of ₹6.44 Cr in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Clinitech Laboratory IPO provide insights into sales growth, market demand, and business scalability.
Clinitech Laboratory recorded an EBITDA of ₹ 101.66 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Clinitech Laboratory Profit After Tax (PAT) is ₹37.12 Cr, reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 643.92 Cr.
EBITDA Margin:
15.79
%
Net Worth: ₹ 354.80 Cr.
Market Capitalisation:
₹ 21.91 Cr.
P/E:
59.03 times
P/BV: 0.06 times
EV/EBITDA: 0.37 times
Clinitech Laboratory operates in Healthcare and Diagnostic And Health Testing And Services.. The Issue is listed on BSE SME in Aug, 2024. Clinitech Laboratory IPO size was 5.78 with Issue price of 96.00 .
Merchant Banker(s) of Clinitech Laboratory IPO: Inventure Merchant Banker Services Private Limited
Clinitech Laboratory IPO subscription was 38.96 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Clinitech Laboratory IPO listed at a listing price of 120.75 against the offer price of 96.00.
The current market price of Clinitech Laboratory is 40.50.
Why Us?
